Thomas Eklund, an experienced financial executive, has been named chairman of the board of directors of Pharmalink AB, which has a late-stage clinical programme targeting IgA nephropathy. Mr Eklund is the former chief executive and head of Europe at Investor Growth Capital AB as well as the former investment director at Alfred Berg ABN AMRO Capital Investment AB. He is currently chairman of the board of Moberg Pharma AB and Itrim AB.
Pharmalink announced the appointment on 24 August 2017.
Copyright 2017 Evernow Publishing Ltd